Welcome to our dedicated page for Strata Critical Medical SEC filings (Ticker: SRTAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Strata Critical Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Strata Critical Medical's regulatory disclosures and financial reporting.
Strata Critical Medical, Inc. filed an amended report to add details about compensation for its new Co-Chief Executive Officers, Melissa Tomkiel and William Heyburn, following the closing of an equity purchase agreement. Effective as of the closing, the board increased each executive’s base salary to $550,000.
Each co-CEO was also granted performance-based restricted stock units (PSUs) under the 2021 Omnibus Incentive Plan, with a target value of $500,000 tied to Passenger business financial targets over the 12 months after closing and $2,000,000 tied to company financial performance over a three-year period. The board approved enhanced equity treatment if either executive is terminated without Cause or resigns for Good Reason, including accelerated vesting of certain time-based awards and prorated vesting of performance awards based on actual results. These terms are reflected in offer letters entered into on August 28, 2025.